The report provides a detailed analysis essential for establishing an Anacetrapib production plant. It encompasses all critical aspects necessary for Anacetrapib production, including the cost of Anacetrapib production, Anacetrapib plant cost, Anacetrapib production costs, and the overall Anacetrapib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Anacetrapib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Anacetrapib is a potent and orally active selective inhibitor of cholesteryl ester transfer protein (CETP). It finds huge applications as an oral drug for the treatment of atherosclerosis, in particular dyslipidemia. It is mainly used for the treatment of elevated cholesterol levels and to prevent cardiovascular diseases by inhibiting CETP activity. Additionally, it is also used as a part of clinical trials to determine its efficacy and potential risks associated with its consumption.
The market for Anacetrapib is largely led by its application as a pharmaceutical compound developed as a cholesteryl ester transfer protein (CETP) inhibitor for the treatment of cardiovascular diseases, which significantly promotes its demand in the pharmaceutical industry. Moreover, its employment in clinical trials and in experimental settings to analyze its safety as a medication for patients with high cholesterol or at risk for heart disease further enhances its demand in the pharmaceutical and biomedical research industries. Furthermore, several factors influence industrial Anacetrapib procurement, such as the availability of raw materials (THF, methylmagnesium chloride, etc.), cost and pricing, compliance with pharmaceutical regulations, quality standards, technological advancements, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.
Raw Material for Anacetrapib Production
According to the Anacetrapib production plant project report, the major raw materials for Anacetrapib production include 2-Fluoro-4-methoxyacetophenone- Tetrahydrofuran- Methylmagnesium Chloride- N-bromosuccinimide- Triisopropylborate-Thionyl Chloride- N,N-dimethylformamide.
Production Process of Anacetrapib
The extensive Anacetrapib production cost report consists of the following industrial production process:
- Production via Chemical synthesis: This method of production involves seven steps to synthesize Anacetrapib as the product. The process is initiated by reacting 2-fluoro-4-methoxyacetophenone with MeMgCl in the presence of CsCl3 in tetrahydrofuran (THF), followed by hydrogenation with Pd/C under acidic conditions in ethanol and bromination with N-bromosuccinimide (NBS) in CH3CN to form a bromide compound. Further, the bromide compound is treated with triisopropylborate and n-BuLi to form boronic acid. Then, the obtained boronic further undergoes Suzuki coupling in the presence of bis(di-t-butylphosphino)ferrocene palladium dichloride in aqueous K2CO3 solution and THF, followed by chlorination with SOCl2 in N,N-dimethylformamide (DMF) and alkylation to obtain Anacetrapib as the final product.
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor having hypocholesterolemic properties. The molecular formula of the compound is C30H25F10NO3, and its molar mass is 637.5 g/mol. Moreover, the density of the compound is 1.345, and its boiling is 555.3°C. It exists in the form of a white to off-white solid that does not dissolve in water. Additionally, the flash point of the compound is 289.641°C, with dissociation constant pka=-2.30±0.60. It is generally stored in temperature conditions below -20oC.